Literature DB >> 19412749

Austrian Hemophilia Registry: design, development and set of variables.

Sylvia Reitter1, Werner Streif, Thomas Schabetsberger, Florian Wozak, Hubert Hartl, Christoph Male, Wolfgang Muntean, Ingrid Pabinger.   

Abstract

Patient registries are databases essential for identifying and tracking individuals with a particular disease and for collecting epidemiological information. The data obtained are necessary for quality control and quality assurance in treatment and for studying the impact of new developments on prevention, diagnosis and treatment. The Austrian Hemophilia Registry is a joint initiative between Austrian hemophilia treaters, represented by the Austrian Hemophilia Society's scientific advisory board, and the Austrian Hemophilia Society (OHG). The registry's main objective is to record information on patients with hemophilia, such as severity of disease, types of treatment and general health status. The registry also aims to improve the planning of supply of factor concentrates and to provide an instrument for early detection of side effects, such as an increase in inhibitor development or certain infections. The registry consists of three parts: the first contains basic information on quality control, the second contains extended data for quality control collected annually, and the third, "study part", covers scientific data and is also updated annually. For the latter, written informed consent of each patient is a prerequisite. Data are stored centrally on a server of an independent, public institution (University for Health Sciences, Medical Informatics and Technology: UMIT). The server is situated in a data-processing center with sophisticated security measures including physical control of access. Participating institutions comprise the main hemophilia care centers in Austria. Statistical analysis is carried out on anonymized data only. The project was financed by a public-private partnership with financial resources provided by the Austrian Ministry of Health (BMGFJ) and the pharmaceutical industry. The entire project, which is planned to be long term, will be monitored, evaluated and adjusted by the scientific advisory board accordingly.

Entities:  

Mesh:

Year:  2009        PMID: 19412749     DOI: 10.1007/s00508-009-1156-0

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  6 in total

1.  From a paper-based transmission of discharge summaries to electronic communication in health care regions.

Authors:  Thomas Schabetsberger; Elske Ammenwerth; Stefan Andreatta; Gordon Gratl; Reinhold Haux; Georg Lechleitner; Klaus Schindelwig; Christian Stark; Raimund Vogl; Immanuel Wilhelmy; Florian Wozak
Journal:  Int J Med Inform       Date:  2005-08-22       Impact factor: 4.046

2.  Medical Data GRIDs as approach towards secure cross enterprise document sharing (based on IHE XDS).

Authors:  Florian Wozak; Elske Ammenwerth; Micheal Breu; Robert Penz; Thomas Schabetsberger; Raimund Vogl; Manfred Wurz
Journal:  Stud Health Technol Inform       Date:  2006

3.  Treatment for haemophilia by postcode.

Authors:  C A Ludlam; C R Hay; G Dolan
Journal:  BMJ       Date:  1997-03-08

4.  E-health approach to link-up actors in the health care system of Austria.

Authors:  Thomas Schabetsberger; Elske Ammenwerth; Ruth Breu; Alexander Hoerbst; Georg Goebel; Robert Penz; Klaus Schindelwig; Herlinde Toth; Raimund Vogl; Florian Wozak
Journal:  Stud Health Technol Inform       Date:  2006

5.  Causes of death in Canadians with haemophilia 1980-1995. Association of Hemophilia Clinic Directors of Canada.

Authors:  I R Walker; J A Julian
Journal:  Haemophilia       Date:  1998-09       Impact factor: 4.287

6.  Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV.

Authors:  Sarah C Darby; Sau Wan Kan; Rosemary J Spooner; Paul L F Giangrande; Frank G H Hill; Charles R M Hay; Christine A Lee; Christopher A Ludlam; Michael Williams
Journal:  Blood       Date:  2007-04-19       Impact factor: 22.113

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.